Aikangte Snags ￥100M in Seris Pre-B Financing

(VCBeat) Jan. 22, 2021-- Aikangte Medical Technology Co., Ltd. ("Aikangte"), an R&D and manufacturing company dedicated to providing comprehensive optical medical solutions, recently raised more than 100 million RMB in a Series Pre-B financing, led by 3H Health Investment and Highlight Capital, with participation from the existing group of Sequoia Capital China, Sherpa Healthcare Partners, Fosun Capital, Green Pine Capital Partners, and YuanBio Venture Capital.

The latest round came less than half A year after Aikangte's Series A round. Proceeds from the transaction will be used to expand businesses in the entire optometric industry, build talent teams worldwide, accelerate the registration and commercialization of many of Aikangte's optometry products, and further develop the pipeline.

Aikangte is a medical device manufacturer in the field of optometry. Its optometry solutions mainly involve prevention and control of myopia among adolescents, correction of vision for adults, a complete series of contact lens care products and optometry equipment. A number of devices developed by Aikangte, including the sclera lens, are the first launch of similar products in the domestic market, which fill the industry gap.

At present, the clinical trials of Aikangte's products are being carried out successively by several well-known domestic large eye hospitals such as the Eye Hospital of Wenzhou Medical University.

3H Health Investment is a dedicated healthcare private equity fund focusing on China. The company invests in pharmaceutical, healthcare services, medical devices, healthcare consumption, and other fields.

HLC is a health industry focused fund. It is dedicated to investing in leading life science enterprises that provide innovative products and services to advance diagnosis and treatment of diseases and to promote healthy living. With extensive experience, the company has established a strong presence across sub-sectors such as biotechnology (innovative therapeutics, CRO/CMO, etc.), medical technology (medical devices, IVD, etc.), and consumer health (hospital chains, personal care, etc.).